Company / SG&A Expense
OCULAR THERAPEUTIX, INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$64.4M
FY2025
5-year range
$22.1M / $64.4M
FY2021-FY2025
Trend
+6.1%
vs FY2024
Sector context
#138 of 213
Health Care
What the data says
At $64M, OCULAR THERAPEUTIX, INC's sg&a expense ranks #76 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $22M in FY2021 to $64M in FY2025.
Based on SEC 10-K filings.
$64M in FY2025 with a 5-year CAGR of +23.8%.
Increased from $34M to $64M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +41.2%
- 5-Year CAGR
- +23.8%
- 10-Year CAGR
- -
Sector benchmark
#76 of 213 in Health CareTop 35% of 213This company $64.4M Sector average $722.3M
▼
-91.1% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +23.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 6.1% year-over-year.
- Ranks #138 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $64.4M | +6.1% |
| FY2024 | $60.7M | +78.7% |
| FY2023 | $33.9M | +48.5% |
| FY2022 | $22.9M | +3.3% |
| FY2021 | $22.1M | +0.0% |
| FY2020 | $22.1M | +42.6% |
| FY2019 | $15.5M | -17.4% |
| FY2018 | $18.8M | +21.1% |
| FY2017 | $15.5M | +40.9% |
| FY2016 | $11.0M | +524.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026